OMS-906 Market Sales Forecast

Key Factors Driving OMS-906 Growth

Market Share Gains and New Patient Starts

• • OMS-906 is positioned as a potentially first-in-class oral antiplatelet therapy designed to address acute coronary syndromes (ACS), an area dominated by intravenous agents in hospital settings.
• • New patient starts are expected to be driven by emergency and early-intervention use, particularly if OMS-906 enables faster initiation of therapy outside catheterization labs.
• • Growing interest from cardiologists and emergency care physicians is supported by the drug’s rapid onset of action combined with oral administration, addressing a key limitation of current IV therapies.
•  Omeros’ strategy focuses on educating interventional cardiology and emergency medicine stakeholders around early platelet inhibition and workflow simplification.

Expansion Across Key Indications

• • Acute Coronary Syndrome (Primary Indication): OMS-906 is being developed for patients presenting with ACS, including myocardial infarction, where immediate platelet inhibition is critical.
• • Pre-Hospital and Early Hospital Settings: The oral profile may allow treatment initiation earlier in the care pathway, potentially expanding use beyond traditional cath-lab environments.
• • Percutaneous Coronary Intervention (PCI) Support: OMS-906 may be positioned as an alternative or complement to IV GP IIb/IIIa inhibitors around PCI procedures.
• • Pipeline and lifecycle opportunities could include broader thrombotic cardiovascular indications, expanding long-term market reach.

Geographic Expansion

• • OMS-906 is being developed with a global cardiovascular market in mind, initially focusing on the United States and Europe, where ACS incidence and interventional cardiology infrastructure are well established.
• • Asia-Pacific represents a meaningful growth opportunity, driven by rising cardiovascular disease prevalence, increasing PCI volumes, and improved access to advanced cardiac care.
  • Omeros is expected to pursue strategic partnerships and regional regulatory engagement to support broader geographic adoption.

New Indication Approvals

• • Regulatory approval of OMS-906 in ACS would significantly broaden treatment options in a space that has seen limited innovation in GP IIb/IIIa inhibition.
• • Future label expansions into adjacent thrombotic or interventional cardiology settings could diversify revenue streams and strengthen competitive positioning.
• Given the high unmet need for safer, more convenient antiplatelet agents, OMS-906 may be positioned for regulatory pathways that recognize clinical\differentiation.

Strong Cardiovascular Volume Momentum

• • Cardiovascular disease remains one of the highest-volume therapeutic areas globally, with ACS representing a substantial share of emergency admissions.
• • Continued growth in PCI procedures and early interventional strategies supports sustained demand for effective platelet inhibition.
• • OMS-906 aligns with trends toward earlier intervention and streamlined acute care pathways, supporting future volume momentum if approved.

Competitive Differentiation and Market Trends

• • OMS-906’s oral small-molecule GP IIb/IIIa inhibitor profile differentiates it from existing intravenous agents such as abciximab and eptifibatide.
• • The potential for rapid platelet inhibition without continuous infusion could improve workflow efficiency and patient management.
• • Broader market trends such as simplification of acute care, preference for oral agents, and value-based cardiovascular care—support OMS-906’s positioning.
• • Increasing emphasis on real-world evidence (RWE) in cardiovascular outcomes is expected to support payer and provider confidence over time.

OMS-906 Recent Developments

•    In December 2025, Omeros Corporation announced the closing of the asset sale and licensing transaction between Omeros and Novo Nordisk for the candidate drug zaltenibart (formerly OMS906). Zaltenibart is a first-in-class, late-stage clinical humanized monoclonal antibody targeting MASP-3 – the most upstream and key activator of the alternative pathway of the complement system – and has shown multiple potential advantages over other alternative pathway inhibitors in development or on the market.
 
“OMS-906 Sales Forecast, and Market Size Analysis – 2034” report provides comprehensive insights of OMS-906 for potential indications like Paroxysmal nocturnal haemoglobinuria and Glomerulonephritis in the 7MM. A detailed picture of OMS-906’s existing usage in approved and anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 –2034 is provided in this report along with a detailed description of the OMS-906 for approved and potential indications. The OMS-906 market report provides insights about OMS-906’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current OMS-906 performance, future market assessments inclusive of the OMS-906 market forecast analysis for approved and potential indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of OMS-906 sales forecasts, along with factors driving its market.

OMS-906 Drug Summary

OMS-906 also known as zaltenibart, is a humanized IgG4 monoclonal antibody that selectively inhibits mannan-binding lectin-associated serine protease-3 (MASP-3), the key activator of complement factor D (CFD) in the alternative complement pathway (AP). By binding to MASP-3, it prevents CFD maturation, thereby suppressing AP activation upstream, which inhibits both intravascular and extravascular hemolysis in paroxysmal nocturnal hemoglobinuria (PNH) more potently than C5 inhibitors, while also showing potential in complement-mediated disorders like C3 glomerulopathy (C3G) and IgA nephropathy (ICGN). Developed by Omeros Corporation (with Novo Nordisk acquiring global rights in 2025 for USD 240 million upfront), it demonstrates dose-proportional pharmacokinetics, rapid suppression of mature CFD, increased hemoglobin, reduced LDH and reticulocytes, and transfusion independence in Phase Ib trials for treatment-naïve and ravulizumab-suboptimal PNH patients, administered via intravenous or subcutaneous routes with a long half-life supporting monthly or less frequent dosing. The report provides OMS-906’s sales, growth barriers and drivers, post usage and approvals in multiple indications.
OMS-906 is in the Phase II stage of clinical development for the treatment of patients with Paroxysmal Nocturnal Hemoglobinuria (NCT06298955) and Glomerulonephritis (NCT06209736).

Scope of the OMS-906 Market Report 

The report provides insights into:

• • A comprehensive product overview including the OMS-906 MoA, description, dosage and administration, research and development activities in potential indications like Paroxysmal nocturnal haemoglobinuria and Glomerulonephritis.
• • Elaborated details on OMS-906 regulatory milestones and other development activities have been provided in OMS-906 market report.
• • The report also highlights OMS-906‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in approved and potential indications across the United States, Europe, and Japan.
• • The OMS-906 market report also covers the patents information, generic entry and impact on cost cut.
• • The OMS-906 market report contains current and forecasted OMS-906 sales for approved and potential indications till 2034.
• • Comprehensive coverage of the late-stage emerging therapies for respective indications.
• • The OMS-906 market report also features the SWOT analysis with analyst views for OMS-906 in approved and potential indications.

OMS-906 Market Report Methodology

The OMS-906 market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

OMS-906 Analytical Perspective by DelveInsight

In-depth OMS-906 Market Assessment

This OMS-906 sales market forecast report provides a detailed market assessment of OMS-906 for potential indications like Paroxysmal nocturnal haemoglobinuria and Glomerulonephritis in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted OMS-906 sales data uptil 2034.

OMS-906 Clinical Assessment

The OMS-906 market report provides the clinical trials information of OMS-906 for approved and potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

OMS-906 Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

OMS-906 Market Potential & Revenue Forecast

• Projected market size for the OMS-906 and its key indications
• Estimated OMS-906 sales potential (OMS-906 peak sales forecasts)
• OMS-906 Pricing strategies and reimbursement landscape

OMS-906 Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• OMS-906 Market positioning compared to existing treatments
• OMS-906 Strengths & weaknesses relative to competitors

OMS-906 Regulatory & Commercial Milestones

• •    OMS-906 Key regulatory approvals & expected launch timelines
• •    Commercial partnerships, licensing deals, and M&A activity

OMS-906 Clinical Differentiation

• OMS-906 Efficacy & safety advantages over existing drugs
• OMS-906 Unique selling points OMS-906 Market Report Highlights 
• • In the coming years, the OMS-906 market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• • The OMS-906 companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence OMS-906’s dominance.
• • Other emerging products for Paroxysmal nocturnal haemoglobinuria and Glomerulonephritis are expected to give tough market competition to OMS-906 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• • A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of OMS-906 in approved and potential indications.
• • Analyse OMS-906 cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• • Our in-depth analysis of the forecasted OMS-906 sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of OMS-906 in approved and potential indications. 

Key Questions Answered in the OMS-906 Market Report

• • What is the class of therapy, route of administration and mechanism of action of OMS-906? How strong is OMS-906’s clinical and commercial performance?
• • What is OMS-906’s clinical trial status in each individual indications such as Paroxysmal nocturnal haemoglobinuria and Glomerulonephritis and study completion date?
• • What are the key collaborations, mergers and acquisitions, licensing and other activities related to the OMS-906 Manufacturers?
• • What are the key designations that have been granted to OMS-906 for approved and potential indications? How are they going to impact OMS-906’s penetration in various geographies?
• • What is the current and forecasted OMS-906 market scenario for approved and potential indications? What are the key assumptions behind the forecast?
• • What are the current and forecasted sales of OMS-906 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?  
• • What are the other emerging products available and how are these giving competition to OMS-906 for approved and potential indications?
• • Which are the late-stage emerging therapies under development for the treatment of approved and potential indications?
• •    How cost-effective is OMS-906? What is the duration of therapy and what are the geographical variations in cost per patient?